479 related articles for article (PubMed ID: 28525622)
1. Dietary Therapy With the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy.
Sigall Boneh R; Sarbagili Shabat C; Yanai H; Chermesh I; Ben Avraham S; Boaz M; Levine A
J Crohns Colitis; 2017 Oct; 11(10):1205-1212. PubMed ID: 28525622
[TBL] [Abstract][Full Text] [Related]
2. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
Yanai H; Levine A; Hirsch A; Boneh RS; Kopylov U; Eran HB; Cohen NA; Ron Y; Goren I; Leibovitzh H; Wardi J; Zittan E; Ziv-Baran T; Abramas L; Fliss-Isakov N; Raykhel B; Gik TP; Dotan I; Maharshak N
Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):49-59. PubMed ID: 34739863
[TBL] [Abstract][Full Text] [Related]
3. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.
Levine A; Wine E; Assa A; Sigall Boneh R; Shaoul R; Kori M; Cohen S; Peleg S; Shamaly H; On A; Millman P; Abramas L; Ziv-Baran T; Grant S; Abitbol G; Dunn KA; Bielawski JP; Van Limbergen J
Gastroenterology; 2019 Aug; 157(2):440-450.e8. PubMed ID: 31170412
[TBL] [Abstract][Full Text] [Related]
4. Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease.
Landorf E; Hammond P; Abu-Assi R; Ellison S; Boyle T; Comerford A; Couper R
J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1279-1286. PubMed ID: 38623960
[TBL] [Abstract][Full Text] [Related]
5. Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease.
Sigall-Boneh R; Pfeffer-Gik T; Segal I; Zangen T; Boaz M; Levine A
Inflamm Bowel Dis; 2014 Aug; 20(8):1353-60. PubMed ID: 24983973
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
Zhou S; Huang Z; Hou W; Lin Y; Yu J
Inflamm Res; 2024 Feb; 73(2):199-209. PubMed ID: 38168701
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Active Crohn's Disease in Children Using Partial Enteral Nutrition Combined with a Modified Crohn's Disease Exclusion Diet: A Pilot Prospective Cohort Trial on Clinical and Endoscopic Outcomes.
Urlep D; Orel R; Kunstek P; Benedik E
Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960328
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Crohn's disease exclusion diet in treatment -naïve children and children progressed on biological therapy: a retrospective chart review.
Jijón Andrade MC; Pujol Muncunill G; Lozano Ruf A; Álvarez Carnero L; Vila Miravet V; García Arenas D; Egea Castillo N; Martín de Carpi J
BMC Gastroenterol; 2023 Jun; 23(1):225. PubMed ID: 37386458
[TBL] [Abstract][Full Text] [Related]
9. Modified Crohn's disease exclusion diet is equally effective as exclusive enteral nutrition: Real-world data.
Niseteo T; Sila S; Trivić I; Mišak Z; Kolaček S; Hojsak I
Nutr Clin Pract; 2022 Apr; 37(2):435-441. PubMed ID: 34339527
[TBL] [Abstract][Full Text] [Related]
10. Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study.
Urlep D; Benedik E; Brecelj J; Orel R
Eur J Pediatr; 2020 Mar; 179(3):431-438. PubMed ID: 31781933
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Crohn's Disease Exclusion Diet for Induction of Remission in Crohn's Disease Adult Patients.
Szczubełek M; Pomorska K; Korólczyk-Kowalczyk M; Lewandowski K; Kaniewska M; Rydzewska G
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836367
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease exclusion diet in children with Crohn's disease: a case series.
Scarallo L; Banci E; Pierattini V; Lionetti P
Curr Med Res Opin; 2021 Jul; 37(7):1115-1120. PubMed ID: 33951997
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
14. Sustained Diet-Induced Remission in Pediatric Crohn's Disease Is Associated With Kynurenine and Serotonin Pathways.
Ghiboub M; Boneh RS; Sovran B; Wine E; Lefèvre A; Emond P; Verburgt CM; Benninga MA; de Jonge WJ; Van Limbergen JE
Inflamm Bowel Dis; 2023 May; 29(5):684-694. PubMed ID: 36637175
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
16. Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease.
Sigall Boneh R; Van Limbergen J; Wine E; Assa A; Shaoul R; Milman P; Cohen S; Kori M; Peleg S; On A; Shamaly H; Abramas L; Levine A
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):752-759. PubMed ID: 32302709
[TBL] [Abstract][Full Text] [Related]
17. Effect of the Crohn's Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn's Disease.
Matuszczyk M; Meglicka M; Wiernicka A; Jarzębicka D; Osiecki M; Kotkowicz-Szczur M; Kierkuś J
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887910
[TBL] [Abstract][Full Text] [Related]
18. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
[TBL] [Abstract][Full Text] [Related]
19. [Anti-TNF therapy in treatment of luminal Crohn's disease].
Marko B; Prka L
Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
[TBL] [Abstract][Full Text] [Related]
20. Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of a pilot study.
Verburgt CM; Dunn KA; Otley A; Heyman MB; Verstraete S; Sunseri W; Sylvester F; de Meij T; Comeau A; Langille M; de Jonge WJ; Benninga MA; Van Limbergen JE
BMJ Open; 2023 Feb; 13(2):e064944. PubMed ID: 36725090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
